In-utero exposure to tenofovir is associated with impaired fetal and infant growth: Need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants

AIDS

Volumn 30, Issue 13, 2016, Pages 2135-2137

  Denneman, Lisanne ^a,b   Cohen, Sophie ^a   Godfried, Mieke H ^c   Van Leeuwen, Elisabeth ^c   Nellen, Jeannine F B ^c   Kuijpers, Taco W ^a   Pajkrt, Dasja ^a   Van De Plas, Atie ^a   Smit, Colette ^d   Weijsenfeld, Anouschka M ^a   Scherpbier, Henriette J ^a   Bunders, Madeleine J ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d STICHTING HIV MONITORING   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

CATCH UP GROWTH; CD4 LYMPHOCYTE COUNT; CHILD GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; FETUS GROWTH; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; LETTER; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PERINATAL DRUG EXPOSURE; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION; BIRTH WEIGHT; CHEMICALLY INDUCED; CHILD DEVELOPMENT; DRUG EFFECT; FEMALE; FETUS DEVELOPMENT; FOLLOW UP; GROWTH DISORDER; INTRAUTERINE GROWTH RETARDATION; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; BIRTH WEIGHT; CHILD DEVELOPMENT; FEMALE; FETAL DEVELOPMENT; FETAL GROWTH RETARDATION; FOLLOW-UP STUDIES; GROWTH DISORDERS; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; TENOFOVIR;

EID: 84982806722     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001156     Document Type: Letter

References (11)

1. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458-465
2. Cooper ER, Charuarat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-494
3. WHO. Global update on HIV treatment 2013: results, impact and opportunities. WHO report in partnership with UNICEF and UNAIDS -June 2013. http://www.unaids.org/en/resources/docu ments/2013/20130630-treatment-report. [Accessed January 2016
4. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva, Switzerland: World Health Organization; June 2013 : ; http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. [Accessed January 2016
5. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29: 207-220
6. Viganò A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C, et al In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infectedmothers.Antivir Ther 2011 16 1259-1266
7. Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, Hazra R, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26: 1151-1159
8. Ransom CE, Huo Y, Patel K, Scott GB, Watts HD, Williams P, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr 2013; 64: 374-381
9. WHO. Guidelines on optimal feeding of low birthweight infants in low-and middle-income countries. Geneva, Switzerland: World Health Organization 2011
10. Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015; 61: 996-1003
11. Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9: e1001217